Shareholder Briefing

HaemaLogiX Shareholders Meeting was held on 13 June 2018. The focus of this meeting was to update our shareholders on the progress made since the last meeting, held on 22 November 2017, and the future regarding our next round of fund raising. In all, there were 17 shareholders in attendance. These shareholders represented 71% of total issued shares.

Our presentation broadly covered the following:

  • KappaMab antibody: A review of our established strategy around the naked antibodies being the KappaMab antibody Phase IIb study, treating a select group of patients with multiple myeloma. This study currently enrolling as an Investigator Initiated Trial (IIT), is being conducted at 6 centers in Melbourne under the leadership of Prof. Andrew Spencer. HaemaLogiX and Celgene Pty Ltd (Celgene) are providing support for this study - HaemaLogiX will provide funding support and Celgene will provide the supply of Revlimid® (lenalidomide), for the combination phase of the study. Stage I of the trial is completed and recruitment of Stage II, is in progress;
  • Kappa CAR-T: A restatement of the HaemaLogiX portfolio was presented. This included an update of the progress following the execution of a CAR T-cell commercialisation agreement with Westmead and WSHLD in July 2017. In addition, following the currently planned preclinical work, we will test the Kappa CAR-T cell in a clinical trial with patients diagnosed with multiple myeloma commencing in the 2nd quarter of 2019. This new technology has generated strong support among the leading clinical research institutions based on remarkable results seen in other blood based cancers; and
  • Lambda therapies: An update of the preclinical work conducted on the Lambda clones held by HaemaLogiX has produced samples of 4 naked antibodies. These antibodies will now be tested and compared to help HaemaLogiX identify a lead candidate to take into the next stage of preclinical testing.

To allow HaemaLogiX to develop these projects, further capital raising is required to fund such trials plus undertake further preclinical work for our early stage LambdaMab asset. A series of key near term value inflection points were highlighted which could lead to an attractive licensing or sale agreement of our lead product(s).

We hope you will follow our progress on this website over the months ahead.